CN117535206A - Lactobacillus salivarius and application thereof - Google Patents
Lactobacillus salivarius and application thereof Download PDFInfo
- Publication number
- CN117535206A CN117535206A CN202410004784.9A CN202410004784A CN117535206A CN 117535206 A CN117535206 A CN 117535206A CN 202410004784 A CN202410004784 A CN 202410004784A CN 117535206 A CN117535206 A CN 117535206A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- strain
- lvagi
- urinaemulieris
- limosilactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186869 Lactobacillus salivarius Species 0.000 title claims abstract description 24
- 210000005002 female reproductive tract Anatomy 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 12
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 241000186660 Lactobacillus Species 0.000 claims description 28
- 229940039696 lactobacillus Drugs 0.000 claims description 25
- 239000001963 growth medium Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 8
- 210000001635 urinary tract Anatomy 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 6
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 6
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 6
- 241001561398 Lactobacillus jensenii Species 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 210000003097 mucus Anatomy 0.000 claims description 5
- 238000012136 culture method Methods 0.000 claims description 4
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000006872 mrs medium Substances 0.000 claims description 2
- 241001134659 Lactobacillus curvatus Species 0.000 claims 2
- 239000002417 nutraceutical Substances 0.000 claims 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims 1
- 229940054346 lactobacillus helveticus Drugs 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 11
- 210000001215 vagina Anatomy 0.000 abstract description 11
- 244000199866 Lactobacillus casei Species 0.000 abstract description 8
- 235000013958 Lactobacillus casei Nutrition 0.000 abstract description 8
- 229940017800 lactobacillus casei Drugs 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 239000004310 lactic acid Substances 0.000 abstract description 6
- 235000014655 lactic acid Nutrition 0.000 abstract description 6
- 210000005000 reproductive tract Anatomy 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 206010018910 Haemolysis Diseases 0.000 abstract description 5
- 230000008588 hemolysis Effects 0.000 abstract description 5
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000009835 boiling Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 244000000010 microbial pathogen Species 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 5
- 201000008100 Vaginitis Diseases 0.000 description 5
- 208000037009 Vaginitis bacterial Diseases 0.000 description 5
- 229960001305 cysteine hydrochloride Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 208000032159 Vaginal inflammation Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000304 virulence factor Substances 0.000 description 4
- 230000007923 virulence factor Effects 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000186146 Brevibacterium Species 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000207202 Gardnerella Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- -1 coatings Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000011177 media preparation Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
- SFAYBQDGCKZKMH-UHFFFAOYSA-N BNCC Chemical compound BNCC SFAYBQDGCKZKMH-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical class [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Chemical class 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940054541 urex Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the field of microorganisms, in particular to lactobacillus salivarius and application thereof. The Lactobacillus casei is characterized by having a preservation number of CCTCC NO: M20231492Limosilactobacillus urinaemulieris) Lvagi-36, the strain is nontoxicThe kit has the advantages of force factor, no drug resistance gene, no hemolysis and good safety. And has the capability of producing lactic acid and hydrogen peroxide, can resist low pH, has good antibacterial capability for genital tract pathogenic bacteria such as Gardner vagina bacteria, and can be applied to preparing female genital tract health products.
Description
Technical Field
The invention relates to the field of microorganisms, in particular to lactobacillus salivarius and application thereof, and particularly relates to lactobacillus salivarius Lvagi-36 and application thereof in female genital tract health.
Background
The female genital tract is an open cavity tract, is lodged with a large number of different kinds of microorganisms, is one of main distribution areas of human microorganisms, and is closely related to female reproductive health. About 300 or more microorganisms are symbiotic in the female genital tract, including bacteria, viruses, fungi, etc., with bacteria being the predominant microorganism. They are constrained and balanced with each other to form dynamic balance, and various vaginitis is related to the imbalance of the vaginal microecological environment.
The microbial composition of the genital tract varies from site to site, and in healthy women of childbearing age most bacteria are present in the lower genital tract (vagina and cervix) and the bacteria in the upper genital tract have not been well characterized to date. The vaginal microbiota has low microbial diversity, and is mainly composed of lactobacillus. The differentiation of dominant lactobacilli in healthy women of different territories and ethnicities can generally divide the vaginal flora into five community (community state types, CST) types. CST-I is mainly composed of Lactobacillus crispatus, CST-II is mainly composed of Lactobacillus gasseri, CST-III is mainly composed of Lactobacillus jensenii, CST-V is mainly composed of Lactobacillus jensenii, and CST-IV has no dominant Lactobacillus group and can be further subdivided into CST IV-A and CST IV-B subtypes, wherein CST IV-B is closely related to bacterial vaginosis (Bacterial Vaginosis, hereinafter referred to as "BV") and mainly composed of anaerobic bacteria such as Bacillus mirabilis, goldebrand bacteria and Gardnerella.
In disease states, the composition of microorganisms and biomass load vary greatly, and multiple pathogens overgrow. The vaginal microecological environment enters a fragile state, is not easy to resist the propagation and invasion of pathogenic bacteria, and causes various vaginal inflammations. Bacterial vaginosis is a common gynecological disease, the infection rate is 15% -52%, and the bacterial vaginosis is a vaginal infectious disease of clinical syndrome caused by dysbacteriosis in vagina due to excessive reproduction of gardnerella vaginalis and other anaerobic bacteria as main substances to replace lactobacillus. BV is reported to be a risk factor for histological choriitis, amniotic fluid infection, post-cesarean endometritis, and other pregnancy defects and pregnancy complications.
Aiming at BV, the clinical treatment method adopts metronidazole or clindamycin, wherein the metronidazole is a precursor drug, and in an anaerobic environment, the nitro of the metronidazole is reduced to amino by the enzymatic reduction in bacterial cells, so that antibiotics are converted into active forms, and then the helical structure of the antibiotics is destroyed by covalent bonding with pathogen DNA and single-strand and double-strand breaks are caused, so that the pathogen DNA is degraded and dead; clindamycin can bind to the 50S ribosomal subunit on the bacterial ribosome, preventing extension of the peptide chain, thereby inhibiting protein synthesis by bacterial cells, resulting in bacterial death. The treatment with antibiotics is quick in effect, but has great defects, and has the following two aspects: (1) The vaginal microecology is not restored to a healthy equilibrium state which can resist pathogenic bacteria invasion after treatment, and the inhibited or killed pathogenic microorganisms or external pathogenic microorganisms can be further propagated and even pathogenic to cause recurrence or new vaginal inflammation; (2) The microorganisms produce drug resistance, and antibiotics cannot balance the vaginal microecological environment, resulting in refractory BV. Thus, although the antibiotic treatment takes effect quickly, the recurrence rate is high, and the recurrence rate is up to 30% within 3 months.
The treatment of the vaginal microecological imbalance comprises three steps of sterilization, mucous membrane repair and restoration of vaginal microecological balance. Sterilization is the first step in the treatment of vaginal inflammation, and inhibits or kills pathogenic microorganisms including hyperproliferative aerobic and anaerobic bacteria, blastospores or hyphae, trichomonas, and the like. After the pathogenic microorganisms are inhibited or killed, the immune repair of the vaginal mucosa and the recovery of dominant lactobacillus are the final targets for treating the colpitis. During this period, if the repair of the vaginal mucosa, the recovery process of lactobacillus is affected, the physical and chemical environment in the vagina is not restored to normal, the suppressed pathogenic microorganisms or the external pathogenic microorganisms can also reproduce again or even cause diseases to cause recurrence or new vaginal inflammation. And probiotics can rapidly occupy the receptors of vaginal epithelium in the vagina to generate a protective effect on the vagina, thereby promoting the vagina to restore to the normal microenvironment and reducing the recurrence of colpitis. Thus, the use of probiotic micro-ecological agents for the treatment of BV is a more preferred approach.
At present, only 2 vaginal microecological medicines are marketed in China, wherein one active ingredient is streptococcus enteritidisStreptococcus faecalis) The method comprises the steps of carrying out a first treatment on the surface of the The other active component is Lactobacillus delbrueckiiLactobacillus delbrueckii). In addition, some drug lines are in the stage of clinical development, such as the European micro-family of live bacteria capsules containing Lactobacillus crispatus Lc262-1, which has recently been subjected to phase 3 clinical trials, and KAL-001 live bacteria capsules containing 4 dominant lactobacilli from Sichuan anaerobic organisms are in phase 2 research. In addition to pharmaceuticals, some oral probiotics have emerged in the art, such as UREX and astart developed in the coltson, which have been widely used in various oral products for female genital tract health, the principle of which is reported to be the transmission of probiotics to the vagina via the oral-intestinal-anal route.
Chinese patent document CN102851248A discloses a lactobacillus jensenii for the control of bacterial vaginosis. Chinese patent document CN107794236A discloses a Lactobacillus crispatus and an application thereof. Chinese patent document CN108004187a discloses a lactobacillus gasseri and its use for preparing a vaginal antibacterial drug.
Because of the abundant diversity of lactobacillus in the vagina of human body, different lactobacillus show different probiotics ability, and the synergy plays a role in the vaginal microenvironment. And the individual difference exists, and the dominant strains in different female vaginas are slightly different, so that the types of the lactobacillus and the probiotics of different strains need to be comprehensively considered when the corresponding lactobacillus for the vagina is selected. Lactobacillus salivarius is a lactobacillus isolated from the genital tract of healthy females and has not been reported in terms of female genital tract health to date.
Disclosure of Invention
The invention firstly provides a lactobacillus mucilaginosus which is a kind of lactobacillus mucilaginosusLimosilactobacillus urinaemulieris) The strain is selected from Lvagi-36 with a preservation number of CCTCC NO: M20231492.
In some embodiments, the strain has a 16S rDNA sequence as set forth in SEQ ID NO. 1.
The invention further provides a culture method of the lactobacillus casei strain, which comprises inoculating lactobacillus casei to a culture medium, and performing proliferation culture to obtain the proliferated lactobacillus casei strain.
In some embodiments, the medium is MRS medium.
The invention further provides a food, a health-care product or a pharmaceutical composition, and the active ingredient of the food, health-care product or pharmaceutical composition contains the lactobacillus casei strain of urinary tract mucus obtained by the culture method.
In some embodiments, the active ingredient of the composition further comprises one or more selected from the group consisting of lactobacillus crispatus, lactobacillus jensenii, lactobacillus johnsonii, lactobacillus delbrueckii, and lactobacillus grignard.
In some embodiments, the lactobacillus salivarius strain is the sole active ingredient.
In addition, the invention also provides application of the lactobacillus urous or the composition in preparing female genital tract health products.
In some embodiments, the female genital tract health product acts as a bacteriostatic or bacteriocidal agent.
In some embodiments, the female genital tract health product is used to inhibit or kill gardnerella vaginalis.
In some embodiments, the lactobacillus salivarius of the present invention has the following identifying characteristics:
1. microscopic examination of the strain to gram-positive Brevibacterium;
2. the colony forms in MRS culture medium are light white semitransparent circular colonies, the middle is convex, and the surface is smooth and moist.
The lactobacillus casei has no virulence factor, no drug resistance gene and no hemolysis, and has good safety. The lactic acid producing capability is strong, the pH value can be reduced, the acid resisting capability is strong, and the reproduction of pathogenic bacteria in genital tract can be inhibited.
The strain preservation information of the invention is as follows:
strain name: lactobacillus mucilaginosus in urinary tractLimosilactobacillus urinaemulieris)Lvagi-36;
Preservation date: 2023, 08, 17;
identification of survival date: 2023, 24 th 08;
preservation unit: china center for type culture collection (China Center for Type Culture Collection, CCTCC), address: university of martial arts, hubei province, post code: 430072, telephone: 027-68754052;
preservation number: cctccc No. M20231492.
Drawings
FIG. 1 is a front view of the colony morphology of Lactobacillus salivarius Lvagi-36.
FIG. 2 is a photograph of a gram stain of Lactobacillus salivarius Lvagi-36.
Description of the embodiments
Definition and description
Lactobacillus salivarius strains of a particular accession number as claimed in the present invention include, but are not limited to:
1. lactobacillus casei of urinary tract with CCTCC NO: M20231492 as the deposited microorganismLimosilactobacillus urinaemulieris) Lvagi-36 strain;
2. a strain of lactobacillus casei having the same genome as the lvagei-36 strain;
3. the passaging strain without mutation based on the aforementioned 1 or 2;
4. a passaging strain based on the aforementioned 1, 2 or 3 that accumulates minute mutations in passaging, but has no substantial change in toxicity, immunogenicity and biological activity;
5. based on the live or inactivated form of the strain according to any of the foregoing 1-4, it may be whole cells or derivatives such as lysates or fermentation products.
As known in the art, strains inevitably introduce minor mutations by the use of progeny, and when mutations occur in non-coding sequence regions or synonymous mutations in coding regions or mutations that do not affect strain toxicity, immunogenicity and biological activity (e.g., residues that may be linked amino acid residues between two domains, or are located within the higher structure of the protein and do not affect toxicity, immunogenicity and biological activity by virtue of not contacting immune cells), it is reasonable to expect that these minor changes do not significantly affect toxicity, immunogenicity and biological activity of the progeny strain, and are derived from the strains contributed by the invention and therefore remain within the substantial technical contribution of the invention. These minor mutations remain insubstantial mutations and should be considered as mutant strains that have no alterations in toxicity, immunogenicity, and biological activity.
There is no substantial change in toxicity, immunogenicity, and biological activity, including, but not limited to, regarding toxicity, immunogenicity, and biological activity as being the same within the limitations and acceptable or unavoidable errors of detection techniques such as detection sensitivity, detection limits, and the like. The toxicity, immunogenicity and biological activity of the L vagi-36 strain offspring were determined by cells, animals, etc., and the expected or unavoidable systematic errors were attributed to insubstantial changes due to differences in cell lines, animal varieties, age, sex, health conditions, culture conditions, etc.
The composition contains the active ingredient lactobacillus salivarius and other ingredients, such as auxiliary ingredients without physiological effects or other functional ingredients.
Functional ingredients include, but are not limited to, other functional strains, or prebiotic ingredients, post-prebiotic ingredients, and the like.
As a preferred mode, the composition of the invention contains other active lactobacilli, such as one or more selected from the group consisting of Lactobacillus crispatus, lactobacillus jensenii, lactobacillus johnsonii, lactobacillus delbrueckii and Lactobacillus grignard.
The auxiliary materials comprise a drug carrier and an excipient. A pharmaceutical carrier refers to a pharmaceutical carrier that does not cause significant irritation to a subject and does not abrogate the biological activity and properties of the administered probiotic. The pharmaceutically acceptable carrier may enhance or stabilize the composition or may be used to facilitate the preparation of the composition. Pharmaceutically acceptable carriers can include solvents, dispersion media, coatings, surfactants, antioxidants, isotonic agents, absorption delaying agents, salts, pharmaceutical stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and the like, and combinations thereof, as known to those skilled in the art (see, e.g., remington's Pharmaceutical Sciences, 18 th edition MackPrinting Company,1990, pages 1289-1329). Unless the conventional carrier is incompatible with the active ingredient, it is contemplated that it will be used in a therapeutic or pharmaceutical composition. The carrier may be selected to minimize adverse side effects in the subject and/or minimize inactivation of the active ingredient.
An excipient refers to a substance that is added to a pharmaceutical composition to give the drug a certain shape or a certain concentration. Such as sterile water, physiological saline, polyalkylene glycols (such as polyethylene glycol), vegetable oils or hydrogenated naphthalenes, calcium bicarbonate, calcium phosphate, various sugars, various types of starch, cellulose derivatives, gelatin, and the like.
The composition of the present invention may be prepared in any form convenient for use, such as powder, tablet, granule, gel, capsule or liquid, which are common in clinical or food.
The compositions of the present invention are administered to a subject in an amount (therapeutically effective amount) and frequency effective to exert efficacy, preferably in a single dose of 10 2 ~10 15 CFU、10 4 ~10 13 CFU or 10 5 ~10 12 Urinary tract mucus lactobacillus of CFULimosilactobacillus urinaemulieris)。
The specific temperature parameters in the present invention, unless specified otherwise, are understood to be constant temperature treatments and allow for variations within a certain temperature interval. Such as within a range of + -5 ℃, + -4 ℃, + -3 ℃, + -2 ℃, + -1 ℃.
The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. It is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments, and that all other embodiments obtained by a person skilled in the art without making creative efforts based on the embodiments in the present invention shall fall within the protection scope of the present invention.
The materials used in the following examples were configured or commercially available as follows:
MRS broth preparation: weighing MRS finished product culture medium (Thermo Scientific ™, CM 0359B) powder 52.0 g, dissolving into 1L distilled water; heating to boil, cooling to room temperature, adding 0.55 g cysteine hydrochloride, stirring to dissolve, and adjusting pH to 6.5; installing quantitative liquid separator and introducing N 2 Heating to boil, boiling for 20 min, cooling, packaging into 10 mL anaerobic tube, sterilizing at 118 deg.C under moist heat for 20 min, storing in shade and in dark place.
MRS solid culture medium preparation: weighing MRS finished product culture medium (Thermo Scientific ™, CM 0359B) powder 52.0 g and agar powder 15.0 g, dissolving into distilled water 1L, boiling, adding cysteine hydrochloride 0.55 g after boiling, adjusting pH to 6.5, sterilizing at 118 deg.C under moist heat for 20 min, and storing in shade and in dark for use.
Hydrogen peroxide semi-quantitative medium preparation: weighing MRS finished product culture medium (Thermo Scientific ™, CM 0359B) powder 52.0 g, agar powder 15.0 g, dissolving in 1L distilled water, adjusting pH to 6.5, sterilizing at 118 deg.C under high temperature and humidity for 20 min, placing into a 50deg.C water bath after sterilization, maintaining for 30 min, adding 3,3', 5' -tetramethyl benzidine (TMB) (final concentration is 0.25 mg/mL) and horseradish peroxidase (HRP) (final concentration is 0.01 mg/mL), and mixing; after cooling and solidifying, the names and the preparation dates of the culture mediums are marked, and the culture mediums are placed in a refrigerator at 4 ℃ for standby.
Preparation of anaerobic PBS: weighing potassium dihydrogen phosphate 0.27 and g, disodium hydrogen phosphate 1.42 and g, sodium chloride 8 and g, and potassium chloride 0.2 and g, dissolving in distilled water 1 and L, heating and boiling, cooling to room temperature, adding cysteine hydrochloride 0.55 and g, stirring and dissolving, adjusting pH to 6.5, loading into quantitative liquid separator, and introducing N 2 Heating to boil, boiling for 30 min, cooling, packaging into 10 mL anaerobic tube, sterilizing at 121deg.C under moist heat for 30 min, and storing in shade and in dark place.
Preparing an anaerobic BHI liquid culture medium: weighing BHI final culture medium (Thermo Scientific ™, CM 1135B) powder 37.0 g, dissolving in distilled water 1L, heating to boil, cooling to room temperatureAdding 0.55. 0.55 g cysteine hydrochloride, stirring for dissolving, adjusting pH to 6.5, adding quantitative liquid separator, and introducing N 2 Heating to boil, boiling for 20 min, cooling, and packaging with N 2 And CO 2 Packaging into 10 mL anaerobic tubes at a ratio of 1:1, sterilizing at 118 deg.C under moist heat for 20 min, and storing in shade and in dark for use.
Preparing an anaerobic BHI semi-solid culture medium: weighing BHI finished medium (Thermo Scientific ™, CM 1135B) powder 37.0 g, dissolving into 1L distilled water; heating to boil, cooling to room temperature, adding 6 g agar powder, 0.55 g cysteine hydrochloride, stirring to dissolve, adjusting pH to 6.5, adding quantitative liquid separator, and introducing N 2 Heating to boil, boiling for 20 min under slight boiling condition, slightly cooling, and packaging with N 2 And CO 2 Packaging into 10 mL anaerobic tubes at a ratio of 1:1, sterilizing at 118 deg.C under moist heat for 20 min, and storing in shade and in dark place.
Example 1 isolation and identification of strains
Collecting vaginal secretion samples of 20-40 years old Chinese healthy women by using a vaginal cotton swab; taking 2 mL aseptic and anaerobic PBS buffer solution in an anaerobic tube filled with the cotton swab, fully vibrating and uniformly mixing, and continuously carrying out ten-fold gradient dilution on the buffer solution; coating 100 mu L of liquid diluted 10000 times on an MRS solid culture medium, placing the solid culture medium in an anaerobic incubator for culture at 37 ℃, after culturing at 48 and h, selecting a plurality of lactobacillus single colonies to respectively culture in an MRS broth culture medium for 24 and h, transferring one part of the cultured bacterial liquid for continuous culture, and extracting bacterial DNA from the other part of the bacterial liquid; amplifying and sequencing bacterial 16S rDNA gene, and comparing the sequencing result with BLAST to determine 3 strains of urinary tract mucus lactobacillusLimosilactobacillus urinaemulieris) Designated as lvagei-35, lvagei-36 and lvagei-42, respectively, and were each preserved with glycerol.
And (3) streaking Lvagi-36 bacterial liquid to an MRS solid culture medium, and carrying out anaerobic static culture at 37 ℃ for 24-48 h, wherein the colony form is a light white semitransparent circular colony, the middle part is convex, the surface is smooth and moist, and the front photograph is shown in figure 1. Taking 1-ring colony on glass slide, and dripping proper amount of sterile ddH 2 O is coated as a thin bacterial liquid layer, and the glass slide is placed on an alcohol lamp and heated until water evaporates, and the glass slide passes through the flame for 2-3 times rapidly to fix the bacterial cells. The staining was then performed according to the gram staining kit instructions (Guangdong CycloKai microorganism technologies Co., ltd., 029010). Microscopic examination, observation and photographing, and the bacterial staining mirror is used for detecting gram-positive Brevibacterium, and the gram-positive Brevibacterium is shown in FIG. 2.
EXAMPLE 2 Whole genome and novel analysis of strains
Lactobacillus salivarius Lvagi-36 was inoculated into 5 mL MRS broth medium, cultured to logarithmic growth phase, and then strain whole genome DNA was extracted and subjected to whole genome sequencing by using Illumina high throughput sequencing platform Novageq 6000. After assembly and annotation by conventional methods, protein sequences were aligned to VFDB (Virulence Factor Databases) and CARD (The Comprehensive Antibiotic Resistance Database) databases for development of virulence factors and drug resistance gene analysis. The results show that the bacterium does not have virulence factors and drug resistance genes.
The novel analysis of the strain was performed using the average nucleotide similarity (Average Nucleotide Identity, ANI). By searching in Genbank, 5 published results were foundLimosilactobacillus urinaemulierisWhole genome, 2 strains were found to be closest to the Lvagi-36 whole genome and below 99.9% by fastanI (v 1.33) comparison, GCA_014838745.1 (98.8562%) and GCA_932750685.1 (97.5773%), respectively. Thus, lvagi-36 is considered to be a novel strain, and the 16S rDNA sequence thereof is shown in SEQ ID NO. 1.
Lactobacillus urinary tract mucus lvegi-36 was preserved in China center for type culture Collection (China Center for Type Culture Collection, CCTCC), with a preservation number of: cctccc No. M20231492.
Example 3 Low pH growth tolerance experiment
Activating: the preserved lactobacillus salivarius was cultured overnight at 37 ℃ with MRS broth activation at pH 6.5.
And (3) switching: transferring the activated bacteria liquid into MRS broth culture medium with pH value of 4-5, and measuring OD every 2-3 h 600 Values.
Comparison of OD 600 Value: screening canRapid proliferation or OD 600 Higher value strains from different samples.
The results show that Lactobacillus salivarius Lvagi-36, lvagi-35 and Lvagi-42 are all capable of growing in low pH environments.
Example 4 lactic acid production test
After the strain was activated, it was transferred to MRS broth, 2 strains were set in parallel, and cultured at 37℃for 48 h, the pH of the Lactobacillus strain solution cultured for 48 h was measured and recorded with a pH 0.5-5.0 test paper, and the strain was selected for liquid chromatography under the following two conditions. The supernatant was diluted 5-fold, pretreated with concentrated sulfuric acid, and filtered through a 0.22 μm needle filter before loading. The liquid chromatography related parameters are as follows:
instrument model: agilent, analytical liquid chromatography 1200
Chromatographic column model: bere, aminex HPX-87H
Mobile phase: 0.005 M H 2 SO 4 At a speed of 0.6 mL/min
Detector and detection wavelength: DAD,207 nm; RID, differential refractive signal
Sample injection amount: 20. mu L.
TABLE 1 lactic acid producing ability of strains and 48 h pH value of culture
Microorganism | Average lactic acid content (mg/L) | Average pH (48 h) |
Lvagi-36 | 13957.5347 | 3 |
Lvagi-35 | 11797.2532 | 3.5 |
Lvagi-42 | 10413.3975 | 3.5 |
The results show that Lactobacillus salivarius Lvagi-36 produces lactic acid to lower pH. Under the same experimental conditions, the lactic acid producing capacity of Lvagi-36 is stronger than that of the homologous strains Lvagi-35 and Lvagi-42.
EXAMPLE 5 Hydrogen peroxide production capability
After the strain was activated, 2. Mu.L of the bacterial solution was spotted in MRS solid medium containing 0.25 mg/mL TMB and 0.01 mg/mL HRP with a pipette, the plates were placed in the same anaerobic sealed tank, an anaerobic gas bag was added, the culture was performed at 37℃and the corresponding plates were removed at 48 h, exposed to air, and after 30 min the color development reaction was observed and recorded by photographing: the blue color produced by Lactobacillus delbrueckii was 4 points, the blue color produced by Lactobacillus delbrueckii was 3 points, the blue color produced by Lactobacillus delbrueckii was 2 points, the blue color was very weak, and the color was 1 point (slight color reaction) and the color was not changed, respectively, 0 points.
TABLE 2 Hydrogen peroxide production capability
Microorganism | Hydrogen peroxide production score-48 h |
Lvagi-36 | 1 |
Lvagi-35 | 1 |
Lvagi-42 | 1 |
The results showed that lactobacillus salivarius produced hydrogen peroxide in both cultures 24 h and 48 h.
Example 6 Gardnerella vaginalis inhibition test
After lactobacillus is activated, 0.1 mL bacterial liquid is evenly mixed with a melted MRS solid culture medium, poured into a 6 cm plate, after complete solidification, the plate is cultivated at 37 ℃ for 48 h, and a puncher with the inner diameter of 6 mm is used for punching holes on the MRS solid culture medium to obtain bacterial cakes; after the gardnerella vaginalis (purchased from Beijing North Injury Biotechnology institute, BNCC 337545) is activated and transferred, the mixture is diluted with 10 times of sterile PBS buffer solution to obtain 10 -1 Mixing diluent 0.5 mL with molten BHI solid culture medium containing 5.25 mL horse serum 5%, pouring into 9 cm plate, completely solidifying, placing lactobacillus cakes on the surface of BHI solid culture medium, symmetrically placing 4 cakes on each plate, placing each strain of bacteria in 2 parallel, placing into anaerobic sealed tank, adding anaerobic gas producing bag, culturing in plate forward direction 48 h, and measuring bacteriostasis zone size with vernier caliper to calculate average value.
TABLE 3 Gardnerella vaginalis inhibition ability
Microorganism | Diameter (mm) -average value of inhibition zone |
Lvagi-36 | 9.12 |
Lvagi-35 | 8.59 |
Lvagi-42 | 8.66 |
The results show that Lactobacillus salivarius Lvagi-36 can effectively inhibit the growth of Gardnerella. Under the same experimental conditions, the antibacterial capacity of the Lvagi-36 is stronger than that of the homologous strains Lvagi-35 and Lvagi-42.
EXAMPLE 7 hemolysis experiment
The deposited lactobacillus salivarius lvagei-36 was inoculated into 5 mL of MRS broth medium at an inoculum size of 10% with enterococcus faecalis (beta hemolysis, CICC23658, purchased from the chinese industrial microorganism strain deposit management center) as a positive control and a blank medium as a negative control. All strains were anaerobically cultured in MRS broth culture medium at 37℃for 12 h to give activated strains. 2.5. Mu.L of each activated strain was inoculated onto Columbia blood plates (Shanghai family, majia biotechnology Co., ltd.) and 3 replicates were set per group. Observations were made after anaerobic incubation at 37℃for 48 h.
The result shows that a completely transparent hemolytic ring with obvious limit is formed around the colony of the positive control strain, and the colony is beta hemolysis; the medium surrounding the colony of lactobacillus salivarius lvegi-36 was unchanged and was gamma-hemolytic, i.e. not hemolytic.
The present invention can be well implemented according to the above-described embodiments. It should be noted that, based on the above structural design, even if some insubstantial modifications or color-rendering are made on the present invention, the essence of the adopted technical solution is still the same as the present invention, so it should be within the protection scope of the present invention.
Claims (9)
1. Lactobacillus salivarius with urinary tract mucusLimosilactobacillus urinaemulieris) The strain is shown as lactobacillus helveticus Lvagi-36 with the preservation number of CCTCC NO: M20231492.
2. Claim(s)The urinary tract mucus lactobacillusLimosilactobacillus urinaemulieris) A method for culturing a strain, which comprises inoculating Lactobacillus curvatus to a culture medium, and performing proliferation culture to obtain a proliferated Lactobacillus curvatus strain.
3. The culture method according to claim 2, wherein the medium is an MRS medium.
4. A food, health product or pharmaceutical composition comprising the Lactobacillus salivarius as defined in claim 1 as active ingredientLimosilactobacillus urinaemulieris) A strain or a strain containing Lactobacillus salivarius obtained by the culture method as claimed in claim 2.
5. The food, nutraceutical, or pharmaceutical composition of claim 4, wherein the active ingredient of the composition further comprises one or more selected from the group consisting of lactobacillus crispatus, lactobacillus jensenii, lactobacillus johnsonii, lactobacillus delbrueckii, and lactobacillus grignard.
6. The food, nutraceutical or pharmaceutical composition of claim 4, wherein the lactobacillus salivarius strain is the sole active ingredient.
7. The urinary tract lactobacillus mucilaginosus of claim 1Limosilactobacillus urinaemulieris) The application of the strain in preparing female genital tract health products.
8. The use according to claim 7, wherein the female genital tract health product is used as a bacteriostatic or bacteriocidal agent.
9. The use according to claim 7, wherein the female genital tract health product is for inhibiting or killing gardnerella vaginalis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410004784.9A CN117535206B (en) | 2024-01-03 | 2024-01-03 | Lactobacillus salivarius and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410004784.9A CN117535206B (en) | 2024-01-03 | 2024-01-03 | Lactobacillus salivarius and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117535206A true CN117535206A (en) | 2024-02-09 |
CN117535206B CN117535206B (en) | 2024-03-29 |
Family
ID=89788381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410004784.9A Active CN117535206B (en) | 2024-01-03 | 2024-01-03 | Lactobacillus salivarius and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117535206B (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112143722A (en) * | 2020-09-29 | 2020-12-29 | 江南大学 | Method for improving soluble expression quantity of 4, 6-alpha-glucosyltransferase |
CN113308405A (en) * | 2021-06-04 | 2021-08-27 | 青岛诺森生物技术有限责任公司 | Novel double-probiotic synergistic composite inoculant and application thereof |
US20220007683A1 (en) * | 2020-07-10 | 2022-01-13 | Lallemand Hungary Liquidity Management Llc | Process for modulating the nutritional value of whole stillage and distillers products associated thereto |
IT202000018901A1 (en) * | 2020-07-31 | 2022-01-31 | Synbalance Srl | PROBIOTIC COMPOSITIONS AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF SKIN DISEASES AND/OR DISORDERS |
CN114452348A (en) * | 2022-04-13 | 2022-05-10 | 深圳德荫堂生物科技有限公司 | Biological agent for inhibiting bad bacteria infection of private parts and production method thereof |
CN114657095A (en) * | 2022-03-22 | 2022-06-24 | 南昌大学 | Lactobacillus fermentum NCU001464 |
US20220330576A1 (en) * | 2019-08-16 | 2022-10-20 | Dupont Nutrition Biosciences Aps | Compositions for gut health |
FR3126991A1 (en) * | 2021-09-16 | 2023-03-17 | Ysopia Biosciences | Bacterial strain in the prevention and/or treatment of inflammatory pathologies |
FR3130557A1 (en) * | 2021-12-21 | 2023-06-23 | Lesaffre Et Compagnie | Use of a bacterial strain Limosilactobacillus fermentum alone or in combination with Saccharomyces cerevisiae to prevent and/or treat vaginal candidiasis |
-
2024
- 2024-01-03 CN CN202410004784.9A patent/CN117535206B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220330576A1 (en) * | 2019-08-16 | 2022-10-20 | Dupont Nutrition Biosciences Aps | Compositions for gut health |
US20220007683A1 (en) * | 2020-07-10 | 2022-01-13 | Lallemand Hungary Liquidity Management Llc | Process for modulating the nutritional value of whole stillage and distillers products associated thereto |
IT202000018901A1 (en) * | 2020-07-31 | 2022-01-31 | Synbalance Srl | PROBIOTIC COMPOSITIONS AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF SKIN DISEASES AND/OR DISORDERS |
CN112143722A (en) * | 2020-09-29 | 2020-12-29 | 江南大学 | Method for improving soluble expression quantity of 4, 6-alpha-glucosyltransferase |
CN113308405A (en) * | 2021-06-04 | 2021-08-27 | 青岛诺森生物技术有限责任公司 | Novel double-probiotic synergistic composite inoculant and application thereof |
FR3126991A1 (en) * | 2021-09-16 | 2023-03-17 | Ysopia Biosciences | Bacterial strain in the prevention and/or treatment of inflammatory pathologies |
WO2023041712A1 (en) * | 2021-09-16 | 2023-03-23 | Ysopia Biosciences | Bacterial strain used in the prevention and/or treatment of inflammatory pathologies |
FR3130557A1 (en) * | 2021-12-21 | 2023-06-23 | Lesaffre Et Compagnie | Use of a bacterial strain Limosilactobacillus fermentum alone or in combination with Saccharomyces cerevisiae to prevent and/or treat vaginal candidiasis |
CN114657095A (en) * | 2022-03-22 | 2022-06-24 | 南昌大学 | Lactobacillus fermentum NCU001464 |
CN114452348A (en) * | 2022-04-13 | 2022-05-10 | 深圳德荫堂生物科技有限公司 | Biological agent for inhibiting bad bacteria infection of private parts and production method thereof |
Non-Patent Citations (2)
Title |
---|
M KSIEZAREK 等: "Limosilactobacillus urinaemulieris sp. nov. and Limosilactobacillus portuensis sp. nov. isolated from urine of healthy women", 《INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY》, 31 March 2021 (2021-03-31) * |
黄华 主编: "《新编实用临床检验指南 第4版》", 30 June 2021, 汕头大学出版社, pages: 111 * |
Also Published As
Publication number | Publication date |
---|---|
CN117535206B (en) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110656060B (en) | Multi-linked lactobacillus composition and application thereof in female vaginal health | |
TWI652343B (en) | Lactobacillus crimper (LACTOBACILLUS Crispatus) and application thereof | |
CN107299065B (en) | Lactobacillus plantarum and application thereof in preparation of vagina bacteriostatic drugs | |
CN110777087B (en) | Lactobacillus johnsonii and application thereof | |
CN108004187A (en) | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines | |
CN111088178B (en) | Produce lactic acid and H 2 O 2 Lactobacillus and application thereof | |
CN110982726B (en) | Lactobacillus crispatus and application thereof | |
US20210330721A1 (en) | High potency stable formulations of vaginal lactobacillus | |
CN107267415B (en) | Lactobacillus reuteri and application thereof in preparing vagina bacteriostatic drug | |
CN108004188B (en) | Lactobacillus rhamnosus and application thereof in preparing vagina bacteriostatic medicine | |
CN110540945B (en) | Lactobacillus jensenii and application thereof in preparing vaginal antibacterial drugs | |
CN112708578A (en) | Lactobacillus crispatus and application thereof | |
CN117535206B (en) | Lactobacillus salivarius and application thereof | |
CN117511826B (en) | Lactobacillus mucilaginosus and application thereof | |
CN117535208B (en) | Lactobacillus crispatus and application thereof in female genital tract health | |
CN117535209B (en) | Lactobacillus brevis and application thereof in female genital tract health | |
CN117535207A (en) | Lactobacillus gasseri and application thereof | |
CN117305187B (en) | Pediococcus acidilactici for improving intestinal health condition and application thereof | |
CN117402794B (en) | Lactobacillus gasseri and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |